Human adamts-1 protein, gene coding the same, pharmaceutical composition, and method for immunologically assaying human adamts-1 protein
AssigneeKureha Chemical Industry Co., Ltd.
InventorsKUNITAKA HIROSE, EIJI INOGUCHI, MICHINORI HAKOZAKI, KEIKO ISHIOKA, YUKAKO ISHIDA, KOUJI MATSUSHIMA, KOUJI KUNO
Life of this patent
Estimating the term…
Abstract
A human ADAMTS-1 protein, a gene encoding the same, a pharmaceutical composition containing the protein as an active ingredient, and a method for immunologically analyzing the human ADAMTS-1 protein are disclosed. The protein can decrease the number of leukocytes and platelets, and at the same time, increase the number of erythrocytes.
Claims24
A protein characterized by containing an amino acid sequence of SEQ ID NO:
- 1:
- 3 Met Asp Ile Cys Arg Ile Arg Leu Arg Lys Lys Arg Phe Val Ser Ser Pro Arg Tyr Val Glu Thr Met Len Val Ala Asp Gln Ser Met Ala Gln Phe His Gly Ser Gly Leu Lys His Tyr Leu Leu Thr Leu Phe Ser Val Ala Ala Arg Leu Tyr Lys His Pro Ser Ile Arg Asn Ser Val Ser Leu Val Val Val Lys Ile Leu Val Ile His Asp Glu Gln Lys Gly Pro Glu Val Thr Ser Asn Ala Ala Leu Thr Leu Arg Asn Phe Cys Asn Trp Gln Lys Gln His Asn Pro Pro Ser Asp Arg Asp Ala Glu His Tyr Asp Thr Ala Ile Leu Phe Thr Arg Gln Asp Leu Cys Gly Ser Gln Thr Cys Asp Thr Leu Gly Met Ala Asp Val Gly Thr Val Cys Asp Pro Ser Arg Ser Cys Ser Val Ile Glu Asp Asp Gly Leu Gln Ala Ala Phe Thr Thr Ala His Glu Leu Gly His Val Phe Asn Met Pro His Asp Asp Ala Lys Gln Cys Ala Ser Leu Asn Gly Val Asn Gln Asp Ser His Met Met Ala Ser Met Leu Ser Asn Leu Asp His Ser Gln Pro Trp Ser Pro Cys Ser Ala Tyr Met Ile Thr Ser Phe Leu Asp Asn Gly His Gly Glu Cys Leu Met Asp Lys Pro Gln Asn Pro Ile Gln Leu Pro Gly Asp Leu Pro Gly Thr Leu Tyr Asp Ala Asn Arg Gln Cys Gln Phe Thr Phe Gly Glu Asp Ser Lys His Cys Pro Asp Ala Ala Ser Thr Cys Ser Thr Leu Trp Cys Thr Gly Thr Ser Gly Gly Val Leu Val Cys Gln Thr Lys His Phe Pro Trp Ala Asp Gly Thr Ser Cys Gly Glu Gly Lys Trp Cys Ile Asn Gly Lys Cys Val Asn Lys Thr Asp Arg Lys His Phe Asp Thr Pro Phe His Gly Ser Trp Gly Pro Trp Gly Pro Trp Gly Asp Cys Ser Arg Thr Cys Gly Gly Gly Val Gln Tyr Thr Met Arg Glu Cys Asp Asn Pro Val Pro Lys Asn Gly Gly Lys Tyr Cys Glu Gly Lys Arg Val Arg Tyr Arg Ser Cys Asn Leu Glu Asp Cys Pro Asp Asn Asn Gly Lys Thr Phe Arg Glu Glu Gln Cys Glu Ala His Asn Glu Phe Ser Lys Ala Ser Phe Gly Ser Gly Pro Ala Val Glu Trp Ile Pro Lys Tyr Ala Gly Val Ser Pro Lys Asp Arg Cys Lys Leu Ile Cys Gln Ala Lys Gly Ile Gly Tyr Phe Phe Val Leu Gln Pro Lys Val Val Asp Gly Thr Pro Cys Ser Pro Asp Ser Thr Ser Val Cys Val Gln Gly Gln Cys Val Lys Ala Gly Cys Asp Arg Ile Ile Asp Ser Lys Lys Lys Phe Asp Lys Cys Gly Val Cys Gly Gly Asn Gly Ser Thr Cys Lys Lys Ile Ser Gly Ser Val Thr Ser Ala Lys Pro Gly Tyr His Asp Ile Val Thr Ile Pro Thr Gly Ala Thr Asn Ile Glu Val Lys Gln Arg Asn Gln Arg Gly Ser Arg Asn Asn Gly Ser Phe Leu Ala Ile Lys Ala Ala Asp Gly Thr Tyr Ile Leu Asn Gly Asp Tyr Thr Leu Ser Thr Leu Glu Gln Asp Ile Met Tyr Lys Gly Val Val Leu Arg Tyr Ser Gly Ser Ser Ala Ala Leu Glu Arg Ile Arg Ser Phe Ser Pro Leu Lys Glu Pro Leu Thr Ile Gln Val Leu Thr Val Gly Asn Ala Leu Arg Pro Lys Ile Lys Tyr Thr Tyr Phe Val Lys Lys Lys Lys Glu Ser Phe Asn Ala Ile Pro Thr Phe Ser Ala Trp Val Ile Glu Glu Trp Gly Glu Cys Ser Lys Ser Cys Glu Leu Gly Trp Gln Arg Arg Leu Val Glu Cys Arg Asp Ile Asn Gly Gln Pro Ala Ser Glu Cys Ala Lys Glu Val Lys Pro Ala Ser Thr Arg Pro Cys Ala Asp His Pro Cys Pro Gln Trp Gln Leu Gly Glu Trp Ser Ser Cys Ser Lys Thr Cys Gly Lys Gly Tyr Lys Lys Arg Ser Leu Lys Cys Leu Ser His Asp Gly Gly Val Leu Ser His Glu Ser Cys Asp Pro Leu Lys Lys Pro Lys His Phe Ile Asp Phe Cys Thr Leu Thr Gln Cys Ser.
A variation functionally equivalent to a protein containing an amino acid sequence of SEQ ID NO:
- 1.
A protein characterized by containing a matrix metalloproteinase domain, a disintegrin domain, and a thrombospondin domain, except for a mouse ADAMTS-1 protein.
A gene containing a base sequence of SEQ ID NO:
- 2:
- 4 ATG GAT ATC TGC AGA ATT CGG CTT AGG AAG AAG CGA TTT GTG TCC AGC CCC CGT TAT GTG GAA ACC ATG CTT GTG GCA GAC CAG TCG ATG GCA GAA TTC CAC GGC AGT GGT CTA AAG CAT TAC CTT CTC ACG TTG TTT TCG GTG GCA GCC AGA TTG TAC AAA CAC CCC AGC ATT CGT AAT TCA GTT AGC CTG GTG GTG GTG AAG ATC TTG GTC ATC CAC GAT GAA CAG AAG GGG CCG GAA GTG ACC TCC AAT GCT GCC CTC ACT CTG CGG AAC TTT TGC AAC TGG CAG AAG CAG CAC AAC CCA CCC AGT GAC CGG GAT GCA GAG CAC TAT GAC ACA GCA ATT CTT TTC ACC AGA CAG GAC TTG TGT GGG TCC CAG ACA TGT GAT ACT CTT GGG ATG GCT GAT GTT GGA ACT GTG TGT GAT CCG AGC AGA AGC TGC TCC GTC ATA GAA GAT GAT GGT TTA CAA GCT GCC TTC ACC ACA GCC CAT GAA TTA GGC CAC GTG TTT AAC ATG CCA CAT GAT GAT GCA AAG CAG TGT GCC AGC CTT AAT GGT GTG AAC CAG GAT TCC CAC ATG ATG GCG TCA ATG CTT TCC AAC CTG GAC CAC AGC CAG CCT TGG TCT CCT TGC AGT GCC TAC ATG ATT ACA TCA TTT CTG GAT AAT GGT CAT GGG GAA TGT TTG ATG GAC AAG CCT CAG AAT CCC ATA CAG CTC CCA GGC GAT CTC CCT GGC ACC TTG TAC GAT GCC AAC CGG CAG TGC CAG TTT ACA TTT GGG GAG GAC TCC AAA CAC TGC CCC GAT GCA GCC AGC ACA TGT AGC ACC TTG TGG TGT ACC GGC ACC TCT GGT GGG GTG CTG GTG TGT CAA ACC AAA CAC TTC CCG TGG GCG GAT GGC ACC AGC TGT GGA GAA GGG AAA TGG TGT ATC AAC GGC AAG TGT GTG AAC AAA ACC GAC AGG AAG CAT TTT GAT ACG CCT TTT CAT GGA AGC TGG GGA CCA TGG GGA CCG TGG GGA GAC TGT TCG AGA ACG TGC GGT GGA GGA GTC CAG TAC ACG ATG AGG GAA TGT GAC AAC CCA GTC CCA AAG AAT GGA GGG AAG TAC TGT GAA GGC AAA CGA GTG CGC TAC AGA TCC TGT AAC CTT GAG GAC TGT CCA GAC AAT AAT GGA AAA ACC TTT AGA GAG GAA CAA TGT GAA GCA CAC AAC GAG TTT TCA AAA GCT TCC TTT GGG AGT GGG CCT GCG GTG GAA TGG ATT CCC AAG TAC GCT GGC GTC TCA CCA AAG GAC AGG TGC AAG CTC ATC TGC CAA GCC AAA GGC ATT GGC TAC TTC TTC GTT TTG CAG CCC AAG GTT GTT GAT GGT ACT CCA TGT AGC CCA GAT TCC ACC TCT GTC TGT GTG CAA GGA CAG TGT GTA AAA GCT GGT TGT GAT CGC ATC ATA GAC TCC AAA AAG AAG TTT GAT AAA TGT GGT GTT TGC GGG GGA AAT GGA TCT ACT TGT AAA AAA ATA TCA GGA TCA GTT ACT AGT GCA AAA CCT GGA TAT CAT GAT ATC GTC ACA ATT CCA ACT GGA GCC ACC AAC ATC GAA GTG AAA CAG CGG AAC CAG AGG GGA TCC AGG AAC AAT GGC AGC TTT CTT GCC ATC AAA GCT GCT GAT GGC ACA TAT ATT CTT AAT GGT GAC TAC ACT TTG TCC ACC TTA GAG CAA GAC ATT ATG TAC AAA GGT GTT GTC TTG AGG TAC AGC GGC TCC TCT GCG GCA TTG GAA AGA ATT CGC AGC TTT AGC CCT CTC AAA GAG CCC TTG ACC ATC CAG GTT CTT ACT GTG GGC AAT GCC CTT CGA CCT AAA ATT AAA TAC ACC TAC TTC GTA AAG AAG AAG AAG GAA TCT TTC AAT GCT ATC CCC ACT TTT TCA GCA TGG GTC ATT GAA GAG TGG GGC GAA TGT TCT AAG TCA TGT GAA TTG GGT TGG CAG AGA AGA CTG GTA GAA TGC CGA GAC ATT AAT GGA CAG CCT GCT TCC GAG TGT GCA AAG GAA GTG AAG CCA GCC AGC ACC AGA CCT TGT GCA GAC CAT CCC TGC CCC CAG TGG CAG CTG GGG GAG TGG TCA TCA TGT TCT AAG ACC TGT GGG AAG GGT TAC AAA AAA AGA AGC TTG AAG TGT CTG TCC CAT GAT GGA GGG GTG TTA TCT CAT GAG AGC TGT GAT CCT TTA AAG AAA CCT AAA CAT TTC ATA GAC TTT TGC ACA CTG ACA CAG TGC AGT TAA.
A pharmaceutical composition characterized by comprising
- (1) a protein containing an amino acid sequence of SEQ ID NO:
- 1,
- (2) a variation functionally equivalent to said protein containing said amino acid sequence of SEQ ID NO:
- 1, or
- (3) a protein containing a matrix metalloproteinase domain, a disintegrin domain, and a thrombospondin domain, and a pharmaceutically or veterinarily acceptable carrier.
A food characterized by comprising
- (1) a protein containing an amino acid sequence of SEQ ID NO:
- 1,
- (2) a variation functionally equivalent to said protein containing said amino acid sequence of SEQ ID NO:
- 1, or
- (3) a protein containing a matrix metalloproteinase domain, a disintegrin domain, and a thrombospondin domain, and a food additive.
A food additive characterized by comprising
- (1) a protein containing an amino acid sequence of SEQ ID NO:
- 1,
- (2) a variation functionally equivalent to said protein containing said amino acid sequence of SEQ ID NO:
- 1, or
- (3) a protein containing a matrix metalloproteinase domain, a disintegrin domain, and a thrombospondin domain.
A method for immunologically analyzing a human ADAMTS-1 protein containing an amino acid sequence of SEQ ID NO:
- 1, characterized in that a sample is brought into contact with an immunologically reactive substance which is reactive specifically to said human ADAMTS-1 protein, and a complex of said human ADAMTS-1 protein and said immunologically reactive substance is detected.
A method for extracorporeally detecting an immunological state, characterized by analyzing a human ADAMTS-1 protein containing an amino acid sequence of SEQ ID NO:
- 1 in a sample.
A method for immunologically analyzing an mRNA of a human ADAMTS-1 protein containing an amino acid sequence of SEQ ID NO:
- 1, characterized in that a sample is brought into contact with a polynucleotide containing a base sequence complementary to that of said mRNA of said human ADAMTS-1 protein, and a complex of said mRNA of said human ADAMTS-1 protein and said gene is detected.
A method for extracorporeally detecting an immunological state, characterized by analyzing an mRNA of a human ADAMTS-1 protein containing an amino acid sequence of SEQ ID NO:
- 1 in a sample.
An agent for analyzing an immunological state, characterized by containing an immunologically reactive substance capable of immunologically reacting a human ADAMTS-1 protein containing an amino acid sequence of SEQ ID NO:
- 1.
An agent for analyzing an immunological state, characterized by containing a polynucleotide containing a base sequence complementary to that of an mRNA of a human ADAMTS-1 protein containing an amino acid sequence of SEQ ID NO:
- 1.
A method for reducing leukocytes, comprising administering to a subject in need thereof,
- (1) a protein containing an amino acid sequence of SEQ ID NO:
- 1,
- (2) a variation functionally equivalent to said protein containing said amino acid sequence of SEQ ID NO:
- 1, or
- (3) a protein containing a matrix metalloproteinase domain, a disintegrin domain, and a thrombospondin domain, in an amount effective therefor.
A method for reducing platelets, comprising administering to a subject in need thereof,
- (1) a protein containing an amino acid sequence of SEQ ID NO:
- 1,
- (2) a variation functionally equivalent to said protein containing said amino acid sequence of SEQ ID NO:
- 1, or
- (3) a protein containing a matrix metalloproteinase domain, a disintegrin domain, and a thrombospondin domain, in an amount effective therefor.
A method for increasing erythrocytes, comprising administering to a subject in need thereof,
- (1) a protein containing an amino acid sequence of SEQ ID NO:
- 1,
- (2) a variation functionally equivalent to said protein containing said amino acid sequence of SEQ ID NO:
- 1, or
- (3) a protein containing a matrix metalloproteinase domain, a disintegrin domain, and a thrombospondin domain, in an amount effective therefor.
Use of
- (1) a protein containing an amino acid sequence of SEQ ID NO:
- 1,
- (2) a variation functionally equivalent to said protein containing said amino acid sequence of SEQ ID NO:
- 1, or
- (3) a protein containing a matrix metalloproteinase domain, a disintegrin domain, and a thrombospondin domain, for preparing a pharmaceutical composition.
Dependencies are inferred from the claim text.